Varicella-zoster virus immune evasion

Immunological Reviews

Volumn 168, Issue , 1999, Pages 143-156

  Abendroth, Allison ^a   Arvin, Ann ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; HERPES ZOSTER; HUMAN; LATENT VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSORY GANGLION; T LYMPHOCYTE; VARICELLA ZOSTER VIRUS; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; DOWN-REGULATION; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON TYPE II; UP-REGULATION;

EID: 0033026512     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01289.x     Document Type: Review

References (123)

1. 1. Arvin A. Varicella-zoster virus. In: Fields B, Knipe D, Howley P, eds. Fields virology. New York: Raven; 1995. p. 2547-2586.
2. 2. Cohen J, Straus S, Varicella zoster virus and its replication. In: Fields B, Knipe D, Howley P, eds. Fields virology. New York: Raven; 1995. p. 2525-2546.
3. 3. Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr 1995;127:518-525.
4. 4. Gershon AA, LaRussa PS. Varicella vaccine. Pediatr Infect Dis J 1998;17:248-249.
5. 5. Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J Gen Virol 1986;67:1759-1816.
6. 6. Ziegler H, et al. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 1997;6:57-66.
7. 7. Kleijnen MF, et al. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J 1997;16:685-694.
8. 8. Browne H, Smith G, Beck S, Minson T. A complex between the MHC class I homologue encoded by human cytomegalovirus and β 2 microglobulin. Nature 1990;347:770-772.
9. 9. Fahnestock ML, Johnson JL, Feldman RM, Neveu JM, Lane WS, Bjorkman PJ. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity 1995;3:583-590.
10. 10. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996;84:769-779.
11. 11. Machold RP, Wiertz EJ, Jones TR, Ploegh HL. The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains. J Exp Med 1997;185:363-366.
12. 12. Ahn K, Angulo A, Ghazal P, Peterson PA, Yang Y, Fruh K. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci USA 1996;93:10990-10995.
13. 13. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci USA 1996;93:11327-11333.
14. 14. Hengel H, et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997;6:623-632.
15. 15. Ahn K, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997;6:613-621.
16. 16. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 1996;383:720-722.
17. 17. Gray WL, Pumphrey CY, Ruyechan WT, Fletcher TM. The simian varicella virus and varicella zoster virus genomes are similar in size and structure. Virology 1992;186:562-572.
18. 18. Roizman B, Sears A. Herpes simplex viruses and their replication. In: Roizman B, Whitley R, Lopez C, eds. The human herpesviruses. New York: Raven; 1993, p. 11-68.
19. 19. Moriuchi H, Moriuchi M, Dean H, Cheung AK, Cohen JI. Pseudorabies virus EPO is functionally homologous to varicella-zoster virus ORF61 protein and herpes simplex virus type 1 ICPO. Virology 1995;209:281-283.
20. 20. Straus SE. From molecular biology to medicine: two decades of achievement in varicella-zoster virus research. Neurology 1995;45:S11-S12.
21. 21. Davison AJ. Varicella-zoster virus. The Fourteenth Fleming Lecture. J Gen Virol 1991;72:475-486.
22. 22. Cohen JI, Seidel KE. Absence of varicella zoster virus (VZV) glycoprotein V does not alter growth of VZV in vitro or sensitivity to heparin. J Gen Virol 1994;75:3087-3093.
23. 23. Davison AJ, Waters DJ, Edson CM. Identification of the products of a varicella-zoster virus glycoprotein gene. J Gen Virol 1985;66:2237-2242.
24. 24. Forghani B, Dupuis KW, Schmidt NJ. Epitopes functional in neutralization of varicella-zoster virus. J Clin Microbiol 1990;28:2500-2506.
25. 15. Forghani B, Ni L, Grose C. Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex. Virology 1994;199:458-462.
26. 26. Fowler WJ, et al. Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus. Virology 1995;214:531-540.
27. 27. Grose C. Glycoproteins of varicella-zoster virus and their herpes simplex virus homologs. Rev Infect Dis 1991;13 (Suppl 11):S960-S963.
28. 28. Keller PM, Davison AJ, Lowe RS, Riemen MW, Ellis RW. Identification and sequence of the gene encoding gpIII, a major glycoprotein of varicella-zoster virus. Virology 1987;157:526-533.
29. 29. Kinchington PR, Ling P, Pensiero M, Moss B, Ruyechan WT, Hay J. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). J Virol 1990;64:4540-4548.
30. 30. Ling P, Kinchington PR, Sadeghi-Zadeh M, Ruyechan WT, Hay J. Transcription from varicella-zoster virus gene 67 (glycoprotein IV). J Virol 1992;66:3690-3698.
31. 31. Nikkels AF, et al. Distribution of varicella-zoster virus gpI and gpII and corresponding genome sequences in the skin. J Med Virol 1995;46:91-96.
32. 32. Pereira L. Function of glycoprotein B homologues of the family herpesviridae. Infect Agents Dis 1994;3:9-28.
33. 33. Yao Z, Jackson W, Forghani B, Grose C. Varicella-zoster virus glycoprotein gpI/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system. J Virol 1993;67:305-314.
34. 34. Yao Z, Grose C. Unusual phosphorylation sequence in the gpIV (gI) component of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex). J Virol 1994;68:4204-4211.
35. 35. Zhu Z, Gershon MD, Gabel C, Sherman D, Ambron R, Gershon A. Entry and egress of varicella-zoster virus: role of mannose 6-phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. Neurology 1995;45:S15-S17.
36. 36. Zhu Z, Gershon MD, Hao Y, Ambron RT, Gabel CA, Gershon AA. Envelopment of varicella-zoster virus: targeting of viral glycoproteins to the trans-Golgi network. J Virol 1995;69:7951-7959.
37. 37. Mo C, Seun J, Sommer M, Arvin A. Characterization of varicella zoster virus glycoprotein K and its role in viral growth. J Virol 1999;73:4197-4207.
38. 38. Zhu Z, Gershon MD, Ambron R, Gabel C, Gershon AA. Infection of cells by varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin. Proc Natl Acad Sci USA 1995;92:3546-3550.
39. 39. Lubinski JM, et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol 1998;72:8257-8263.
40. 40. Caunt AE. The growth of varicella-zoster virus in tissue fragments. Br J Exp Pathol 1969;50:26-31.
41. 41. Taylor-Robinson D, Caunt A. Varicella virus. Berlin: Springer-Verlag; 1972.
42. 42. Baudoux L, Defechereux P, Schoonbroodt S, Merville MP, Rentier B, Piette J. Mutational analysis of varicella-zoster virus major immediate-early protein IE62. Nucleic Acids Res 1995;23:1341-1349.
43. 43. Kinchington PR, Hougland JK, Arvin AM, Ruyechan WT, Hay J. The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol 1992;66:359-366.
44. 44. Meier JL, Straus SE. Interactions between varicella-zoster virus IE62 and cellular transcription factor USF in the coordinate activation of genes 28 and 29. Neurology 1995;45:S30-S32.
45. 45. Perera LP, Mosca JD, Sadeghi-Zadeh M, Ruyechan WT, Hay J. The varicella-zoster virus immediate early protein, 1E62, can positively regulate its cognate promoter. Virology 1992;191:346-354.
46. 46. Perera LP, Mosca JD, Ruyechan WT, Hayward GS, Straus SE, Hay J. A major transactivator of varicella-zoster virus, the immediate-early protein IE62, contains a potent N-terminal activation domain. J Virol 1993;67:4474-4483.
47. 47. Kinchington PR, Bookey D, Turse SE. The transcriptional regulatory proteins encoded by varicella-zoster virus open reading frames (ORFs) 4 and 63, but not ORF 61, are associated with purified virus particles. J Virol 1995;69:4274-4282.
48. 48. Cohen JI, Seidel K. Varicella-zoster virus (VZV) open reading frame 10 protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for VZV replication in vitro. J Virol 1994;68:7850-7858.
49. 49. Kost RG, Kupinsky H, Straus SE. Varicella-zoster virus gene 63; transcript mapping and regulatory activity. Virology 1995;209:218-224.
50. 50. Moriuchi H, Moriuchi M, Smith HA, Cohen JI. Varicella-zoster virus open reading frame 4 protein is functionally distinct from and does not complement its herpes simplex virus type 1 homolog, ICP27. J Virol 1994;68:1987-1992.
51. 51. Perera LP, Kaushal S, Kinchington PR, Mosca JD, Hayward GS, Straus SE. Varicella-zoster virus open reading frame 4 encodes a transcriptional activator that is functionally distinct from that of herpes simplex virus homology ICP27. J Virol 1994;68:2468-2477.
52. 52. Moriuchi H, Moriuchi M, Straus SE, Cohen JI. Varicella-zoster virus open reading frame 10 protein, the herpes simplex virus VP16 homolog, transactivates herpesvirus immediate-early gene promoters. J Virol 1993;67:2739-2746.
53. 53. Moriuchi H, Moriuchi M, Straus SE, Cohen JI. Varicella-zoster virus (VZV) open reading frame 61 protein transactivates VZV gene promoters and enhances the infectivity of VZV DNA. J Virol 1993;67:4290-4295.
54. 54. Defechereux P, Melen L, Baudonx L, Merville-Louis MP, Rentier B, Piette J. Characterization of the regulatory functions of varicella-zoster virus open reading frame 4 gene product. J Virol 1993;67:4379-4385.
55. 55. Webster CB, Chen D, Horgan M, Olivo PD. The varicella-zoster virus origin-binding protein can substitute for the herpes simplex virus origin-binding protein in a transient origin-dependent DNA replication assay in insect cells. Virology 1995;206:655-660.
56. 56. Piette J, Defechereux P, Baudoux L, Debrus S, Merville MP, Rentier B. Varicella-zoster virus gene regulation. Neurology 1995;45:S23-S27.
57. 57. Heineman TC, Cohen JI. The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22. J Virol 1995;69:7367-7370.
58. 58. Stevenson D, Colman KL, Davison AJ. Characterization of the putative protein kinases specified by varicella-zoster virus genes 47 and 66. J Gen Virol 1994;75:317-326.
59. 59. Myers MG. Viremia caused by varicella-zoster virus: association with malignant progressive varicella. J Infect Dis 1979;140:229-233.
60. 60. Koropchak CM, Solem SM, Diaz PS, Arvin AM. Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J Virol 1989;63:2392-2395.
61. 61. Koropchak CM, et al. Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella [published erratum appears in J Infect Dis 1992;165:188]. J Infect Dis 1991;163:1016-1022.
62. 62. Sawyer MH, et al. Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella. J Infect Dis 1992;166:885-888.
63. 63. Ozaki T, Masuda S, Asano Y, Kondo K, Namazue J, Yamanishi K. Investigation of varicella-zoster virus DNA by the polymerase chain reaction in healthy children with varicella vaccination. J Med Virol 1994;42:47-51.
64. 64. Ozaki T, et al. Viremic phase in nonimmunocompromised children with varicella. J Pediatr 1984;104:85-87.
65. 65. Perera LP, Mosca JD, Ruyechan WT, Hay J. Regulation of varicella-zoster virus gene expression in human T lymphocytes [published erratum appears in J Virol 1995;69:2723]. J Virol 1992;66:5298-5304.
66. 66. Asano Y, et al. Severity of viremia and clinical findings in children with varicella. J Infect Dis 1990;161:1095-1098.
67. 67. Feldman S, Epp E. Detection of viremia during incubation of varicella. J Pediatr 1979;94:746-748.
68. + T lymphocytes and epidermal cells in SCID-hu mice. J Virol 1995;69:5236-5242.
69. 69. Moffat JF, Zerboni L, Kinchington PR, Grose C, Kaneshima H, Arvin AM. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 1998;72:965-974.
70. 70. Lever W, Schaumburg-Lever G. Histopathology of the skin. Philadelphia: JB Lippincott; 1990.
71. 71. Nikkels AF, et al. Comparative immunohistochemical study of herpes simplex and varicella-zoster infections. Virchows Arch A Pathol Anat Histopathol 1993;422:121-126.
72. 72. Straus SE, et al. N1H conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention [published erratum appears in Ann Intern Med 1988;109:438-439]. Ann Intern Med 1988;108:221-237.
73. 73. Gilden DH, Mahalingam R, Ducland AN, Cohrs R. Herpes zoster: pathogenesis and latency. Prog Med Virol 1992;39:19-75.
74. 74. Lungu O, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA 1995;92:10980-10984.
75. 75. Straus SE. Overview; the biology of varicella zoster virus infection. Ann Neurol 1994;35:54-58.
76. 76. Gilden DH, Rozenman Y, Murray R, Devlin M, Vatai A. Detection of varicella-zoster virus nucleic acid in neurons of normal human thoracic ganglia. Ann Neurol 1987;22:377-380.
77. 77. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-126.
78. 78. Bowden RA, Levin MJ, Giller RH, Tubergen DG, Hayward AR. Lysis of varicella zoster virus infected cells by lymphocytes from normal humans and immunosuppressed pediatric leukaemic patients. Clin Exp Immunol 1985;60:387-395.
79. 79. Ihara T, Starr SE, Ito M, Douglas SD, Arbeter AM. Human polymorphonuclear leukocyte-mediated cytotoxicity against varicella-zoster virus-infected fibroblasts. J Virol 1984;51:110-116.
80. 80. Arvin AM, Kushner JH, Feldman S, Bachner RL, Hammond D, Merigan TC. Human leukocyte interferon for the treatment of varicella in children with cancer. N Engl J Med 1982;306:761-765.
81. 81. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 1986;154:422-429.
82. 82. Wallace MR, et al. Tumor necrosis factor, interleukin-2, and interferon-γ in adult varicella. J Med Virol 1994;43:69-71.
83. 83. Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 1992;166 (Suppl 1);S35-S41.
84. 84. Arvin A. Varicella zoster virus: virologic and immunologic aspects of persistent infection. In: Ahmed R, Chen I, eds. Persistent viral infections. New York: John Wiley & Sons Ltd; 1998. p. 183-208.
85. 85. Patel PA, Yoonessi S, O'Malley J, Freeman A, Gershon A, Ogra PL. Cell-mediated immunity to varicella-zoster virus infection in subjects with lymphoma or leukemia. J Pediatr 1979;94:223-230.
86. 86. Gershon AA, Steinberg SP. Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections. Infect Immun 1979;25:170-174.
87. 87. Zhang Y, Cosyns M, Levin MJ, Hayward AR. Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol 1994;98:128-133.
88. 88. Jenkins DE, Redman RL, Lam EM, Liu C, Lin I, Arvin AM. Interleukin (IL)-10, IL-12, and interferon-γ production in primary and memory immune responses to varicella-zoster virus. J Infect Dis 1998;178:940-948.
89. 89. Weigle KA, Grose C. Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation. J Infect Dis 1984;149:741-749.
90. 90. Arvin AM, et al. Immunity to varicella-zoster viral glycoproteins, gpI (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol 1986;137:1346-1351.
91. 91. Brunell PA, Novelli VM, Keller PM, Ellis RW. Antibodies to the three major glycoproteins of varicella zoster virus: search for the relevant host immune response. J Infect Dis 1987;156:430-435.
92. 92. Grose C, Litwin V. Immunology of the varicella-zoster virus glycoproteins. J Infect Dis 1988;157:877-881.
93. 93. Hayward AR. T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J Virol 1990;64:651-655.
94. 94. Sharp M, et al. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis 1992;165:852-858.
95. 95. Cooper EC, Vujcic LK, Quinnan GV, Jr. Varicella zoster virus-specific HLA-restricted cytotoxicity of normal immune adult lymphocytes after in vitro stimulation. J Infect Dis 1988;158:780-788.
96. 96. Diaz PS, Smith S, Hunter E, Arvin AM. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 1989;142:636-641.
97. 97. Hayward A, Giller R, Levin M. Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes. Viral Immunol 1989;2:175-184.
98. 98. Hayward AR, Pontesilli O, Herberger M, Laszlo M, Levin M. Specific lysis of varicella zoster virus infected B lymphoblasts by human T cells. J Virol 1986;58:179-184.
99. 99. Hickling JK, Borysiewicz LK, Sissons JG. Varicella-zoster virus-specific cytotoxic T lymphocytes (Tc):detection and frequency analysis of HLA class I-restricted Tc in human peripheral blood. J Virol 1987;61:3463-3469.
100. + human T-cell clones. J Virol 1992;66:2664-2669.
101. 101. Arvin A. Clinical manifestations of varicella and herpes zoster and the immune response to varicella-zoster virus. In: Hyman R, ed. The natural history of varicella-zoster virus. New York: CRC Press; 1987. p. 67-130.
102. 102. Camitta B, Chusid MJ, Starshak RJ, Gottschall JL. Use of irradiated lymphocytes from immune donors for treatment of disseminated varicella. J Pediatr 1994;124:593-596.
103. 103. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest 1980;65:869-878.
104. 104. Meyers JD, Flournoy N, Thomas ED. Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant. J Infect Dis 1980;141:479-487.
105. 105. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981;32:24-27.
106. 106. Webster A, Grint P, Brenner MK, Prentice HG, Griffiths PD. Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol 1989;27:117-119.
107. 107. Fruh K, Ahn K, Peterson PA. Inhibition of MHC class I antigen presentation by viral proteins. J Mol Med 1997;75:18-27.
108. 108. Johnson DC, Hill AB. Herpesvirus evasion of the immune system. Curr Top Microbiol Immunol 1998;232:149-177.
109. 109. Ploegh HL. Viral strategies of immune evasion. Science 1998;280:248-253.
110. 110. Hengel H, Koszinowski UH. Interference with antigen processing by viruses. Curr Opin Immunol 1997;9:470-476.
111. 111. Heise MT, Pollock JL, O'Guin A, Barkon ML, Bormley S, Virgin HWT. Murine cytomegalovirus infection inhibits IFN γ-induced MHC class II expression on macrophages: the role of type I interferon. Virology 1998;241:331-344.
112. 112. Miller DM, et al. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med 1998;187:675-683.
113. 113. Cohen JI. Infection of cells with varicella-zoster virus down-regulates surface expression of class I major histocompatibility complex antigens. J Infect Dis 1998;177:1390-1393.
114. 114. Moffat JF, et al. The ORF47 and ORF66 purative protein kinases of varicella zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci USA 1998;95:11969-11974.
115. + T lymphocytes. Cell 1994;77:525-535.
116. 116. Campbell AE, Slater JS. Down-regulation of major histocompatibility complex class I synthesis by murine cytomegalovirus early gene expression. J Virol 1994;68:1805-1811.
117. 117. Del Val M, et al. Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J Exp Med 1992;176:729-738.
118. 118. Hill A, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375:411-415.
119. 119. Ahn K, et al. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J 1996;15:3247-3255.
120. 120. Früh K, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-418.
121. 121. Tomazin R, et al. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J 1996;15:3256-3266.
122. + phenotype. J Immunol 1991;146:257-264.
123. 123. Zarling JM, Moran PA, Burke RL, Pachl C, Berman PW, Iasky LA. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD. J Immunol 1986;136:4669-4673.